Medicago, GSK Report 71% Efficacy Rate From Plant-Based COVID-19 Vaccine Study

Quebec-based biopharmaceutical firm Medicago and healthcare conglomerate GlaxoSmithKline (NYSE: GSK) announce today the results from its global Phase 3 efficacy study of its COVID-19 vaccine candidate. The data showed an overall efficacy rate of 71% against all variants of SARS-CoV-2, the virus that causes the pandemic disease.

The Canadian firm’s plant-based vaccine candidate is combined with GSK’s pandemic adjuvant. The firm is using a unique technology to produce virus-like particles, designed to mimic the virus structure for the immune system to recognize ahead of the potential infection.

The study, started in March 2021, was conducted with over 24,000 subjects ages 18 years old and above across Canada, the United States, the United Kingdom, Mexico, Argentina, and Brazil. The vaccine was administered in two doses of 3.75 µg, 21 days apart.

The vaccine candidate also showed a 75.3% efficacy rate specifically against the Delta variant and 88.6% against the Gamma variant. The emerging Omicron variant has not been considered yet in the study.

During the study, the firm reported no related serious adverse events while reactions to the vaccine were “generally mild to moderate and transient”, with “symptoms lasting on average only 1 to 3 days.”

The biopharmaceutical firm plans to seek regulatory approval from Health Canada as part of its rolling submission. The phase 3 results are also expected to be released in a peer-reviewed publication.


Information for this briefing was found via the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Antimony Resources Drills 5.27% Sb Over 4.95 Metres In Latest Results

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Related News

Auditor General Cites $27.4 Billion COVID Benefit Payments Still Unverified, $4.6 Billion Overpayments To Ineligible Recipients

The report also noted the successful speed in obtaining and distributing COVID-19 vaccines but millions...

Wednesday, December 7, 2022, 07:56:44 AM

Datametrex Signs 9 Additional Film & Television Productions For COVID-19 Testing

Datametrex AI (TSXV: DM) this morning provided an update to the market related to its...

Thursday, December 17, 2020, 08:56:44 AM

Well Health Begins Offering Direct To Consumer COVID-19 Antibody Tests In Ontario

Well Health Technologies (TSX: WELL) is getting on the COVID-19 testing trend. The company this...

Thursday, December 3, 2020, 08:17:28 AM

China Protestors Have Zero Tolerance For China’s Zero COVID Policy

Beijing attempts to walk back on its stringent pandemic measures as uprising has been gaining...

Tuesday, November 29, 2022, 10:23:00 AM

Trump Signs $2.3 Trillion Covid-19 Stimulus and Spending Bill on Hopes Congress Votes to Increase Payouts to $2,000

Following months of deadlock between US lawmakers, a second Covid-19 stimulus bill was finally agreed...

Tuesday, December 29, 2020, 10:38:00 AM